Sorin received FDA approval to bring to the U.S. market its Mitroflow aortic heart valve with Phospholipid Reduction Treatment (PRT). Already approved in Europe three years ago, the material treatment is designed to help prevent calcification on the surface of the device by reducing the phospholipid content on the valve.
The Mitroflow valve itself has been around for three decades with a proven track record, and the new phospholipid treatment will hopefully make it last in situ considerably longer than previous models.
Flashback: Mitroflow Aortic Pericardial Heart Valve with Phospholipid Reduction Treatment Gets EU OK…
Product page: Mitroflow with PRT…
Press release: Sorin Group Receives FDA Approval For The Mitroflow(TM) Aortic Heart Valve With New Phospholipid Reduction Treatment…